Objective: To determine if there are differences in the activity of 17␤-hydroxysteroid dehydrogenase and 5␣-reductase (responsible for the production of testosterone and dihydrotestosterone, respectively) in sebaceous glands obtained from men and women with and without acne.
S
EBUM PRODUCTION is stimulated by androgens and is key in the development of acne vulgaris. [1] [2] [3] [4] Several investigators have looked for direct relationships between serum androgen levels, sebum secretion rate, and the presence of acne. 5 The presence of acne in prepubertal girls and sebum production in both sexes correlate with serum dehydroepiandrosterone sulfate (DHEAS) levels. 6, 7 Dehydroepiandrosterone sulfate is an adrenal precursor for synthesis of more potent androgens, such as testosterone and dihydrotestosterone (DHT). Although increased serum androgen levels correlate with the presence of severe nodular acne in men and women, these levels are often within the normal range in mild to moderate acne. 8 This raises the question of whether there is an increased local production of androgens within the sebaceous gland (SG) of patients with acne vulgaris that leads to increased sebum secretion. 9, 10 The SG possesses each of the steroid metabolizing enzymes needed to convert DHEAS to DHT [11] [12] [13] (Figure 1 ). 3␤-Hydroxysteroid dehydrogenase (3␤-HSD) reduces dehydroepiandrosterone to androstenedione. Two isozymes have been identified. 14 17␤-Hydroxysteroid dehydrogenase (17␤-HSD) is a reversible enzyme that can use different nucleotide cofactors and act either as an oxidase (to produce androstenedione from testosterone) or as a reductase (to produce testosterone from androstenedione). Recently, 6 isozymes of 17␤-HSD have been described. 15, 16 The type 2 isozyme is biochemically active in human SGs. 17 Two isozymes of 5␣-reductase (5␣-R) (type 1 and type 2) have been identified. [18] [19] [20] The type 1 isozyme of 5␣-R is predominant in SGs and is present in higher levels in acne-
For editorial comment see page 1101
STUDY prone skin than in skin obtained from regions not prone to acne. 21, 22 To date, no studies have been done to determine if there are sex-related differences in the activity of 17␤-HSD and 5␣-R in human sebaceous glands. Furthermore, it is not known if the activity of these enzymes is greater in SGs isolated from subjects with acne than in SGs from subjects without acne. The goal of this study was to determine if there are differences in the activity of 17␤-HSD and 5␣-R in SGs based on sex or the presence of acne. Serum androgen levels were determined and compared with tissue enzyme activity.
RESULTS
A total of 34 subjects were studied: 8 women with acne (mean ± SD age, 31 ± 5 years), 10 women without acne (mean age, 33 ± 7 years), 8 men with acne (mean age, 26 ± 7 years), and 8 men without acne (mean age, 34 ± 7 years). The acne grade was mild in all subjects examined. The mean (±SEM) total lesion counts in men and women with acne were 41 ± 9 and 44 ± 7, respectively.
TISSUE ENZYME ACTIVITIES
Activities of 5␣-R and of 17␤-HSD in SG from the forehead were compared in men and women with and without acne ( Table 1) . No significant differences were noted in enzyme activity based on the presence of acne in ei-
SUBJECTS AND METHODS

SUBJECTS
The study was approved by the institutional review board of Pennsylvania State University College of Medicine, Hershey. Men and women aged 18 to 45 years with and without acne were recruited especially for this study. Subjects with acne were defined as having a minimum of 15 comedones and 10 inflammatory papules on the face. Subjects were excluded if they had received oral antibiotics within 1 month before the study; used topical acne medications such as antibiotics, benzoyl peroxide, or tretinoin within 2 weeks before the study; received treatment in the past with oral retinoids; had known underlying endocrine disease, such as congenital adrenal hyperplasia, polycystic ovary syndrome, or adrenal or ovarian tumor; or were currently using oral contraceptives, contraceptive injection, implantable contraceptives, estrogens, prednisone, other corticosteroids, or finasteride.
PROCEDURES
All women were studied in the luteal phase of their menstrual cycle. Blood samples were taken for serum DHEAS, androstenedione, total and free testosterone, DHT, and 3␣-androstanediol glucuronide. Skin biopsies of the forehead were performed as follows. A 12-mm elliptical excision (4 mm at its widest point) was made from each side of the forehead, approximately 6 mm from the hairline. Skin was excised in the subcutaneous layer and a layered closure was performed. Skin specimens were transported on ice to the dermatology laboratory, where microdissections were performed according to previously described techniques. 22 Biochemical assays for the activities of 17␤-HSD and 5␣-R were performed on isolated SG as previously described. 22, 23 Samples were incubated at 37°C at pH 5 and 7. Incubations for 5␣-R were carried out for 30 minutes, and those for 17␤-HSD were carried out for 60 minutes. The substrate for the 5␣-R reaction was tritiated testosterone (10 6 disintegrations per minute) in the presence of 10-µmol/L cold testosterone and 500-µmol/L nicotinamide adenine dinucleotide phosphate as a cofactor. The same isotope was used as the substrate for the oxidative reaction of 17␤-HSD, but nicotinamide adenine dinucleotide (1 µmol/L) was used as the cofactor. Tritiated androstenedione (10 6 disintegrations per minute) in the presence of 10-µmol/L cold androstenedione was used as the substrate for the reductive activity of 17␤-HSD, and nicotinamide adenine dinucleotide reduced (1 µmol/L) was used as the cofactor.
Enzyme activity was calculated by means of the net percentage conversion of substrate, the molar concentration of substrate, and the incubation volume. To account for potential differences in the sizes of SG assayed and, hence, differences in enzyme activity, data were normalized to SG protein concentration. Data are expressed as picomoles of product per minute per milligram of protein.
SERUM ANDROGENS
Serum levels of DHEAS, testosterone, DHT, and 3␣-androstanediol glucuronide were determined by means of radioimmunoassay methods previously described.
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DATA ANALYSIS
Unpaired t tests on log base 10 transformed data were used to compare enzyme activity between men and women and subjects with and without acne. The same test was used to compare serum androgens between groups. A paired t test using log transformed data was used to compare activity of different enzymes within the same groups. Correlation coefficients between enzyme activities in the SG and serum androgen levels were determined on the basis of sex and the presence of acne. Significance of the correlation was tested at a 95% confidence interval with Fisher r to z test. ther men or women. Although the mean activities of 5␣-R and 17␤-HSD were higher in SG from women with acne than women without acne, these differences did not achieve statistical significance (P = .08 and .19, respectively).
The mean tissue enzyme activities of 5␣-R, reductive 17␤-HSD, and oxidative 17␤-HSD were significantly greater in men than women, with respective P values of .05, less than .001, and .004 (unpaired t test) (Figure 2) .
The mean activity (±SEM) of 5␣-R in SG was significantly greater than both the reductive and oxidative activity of 17␤-HSD in all groups of subjects studied. Corresponding P values are given in Table 1 .
SERUM ANDROGENS
Mean serum levels (±SEM) of DHEAS, androstenedione, testosterone, free testosterone, and DHT (but not 3␣-androstanediol glucuronide) were significantly greater in women with acne than women without acne, by unpaired t test ( Table 2) . No differences in serum androgen levels were noted in men on the basis of the presence of acne.
CORRELATION OF TISSUE ENZYME ACTIVITY AND SERUM ANDROGEN LEVELS
Tissue enzyme activity correlated with serum androgen levels only in women without acne. Reductive activity of 17␤-HSD correlated with serum androstenedione level (r = 0.948, PϽ.001) and total testosterone level (r = 0.673, P = .04). Activity of 5␣-R in SG correlated with serum androstenedione level (r = 0.658, P = .04) and DHT level (r = 0.671, P = .03). No correlation was noted between tissue enzyme activity and serum androgens in women with acne or in men with or without acne.
COMMENT
The relationship between serum androgen concentrations and the local production of androgens within sebaceous glands is not clear. Acne is associated with elevated serum androgen levels in women with virilizing tumors and with elevated serum DHEAS levels in both men and women with partial adrenal hydroxylase deficiencies. 8 Whether androgens from the systemic circulation act directly to stimulate the sebaceous glands or whether they act indirectly to stimulate enzymes involved in androgen production within the sebaceous gland itself is not known.
TISSUE ENZYME ACTIVITIES IN SUBJECTS WITH AND WITHOUT ACNE
Our data fail to demonstrate any significant difference in tissue enzyme activity based on the presence of acne. Although a trend toward higher 5␣-R activity and reductive activity of 17␤-HSD was noted in SG from women with acne compared with women without acne, the power to detect such a difference in this study may have been limited by the small sample size. Mean ± SEM activity of 5␣-reductase (5␣-R) and reductive and oxidative 17␤-hydroxysteroid dehydrogenase (17␤-HSD) in sebaceous glands from men and women. Activity of all 3 enzymes was significantly greater in men than women, with respective P values of .05 (asterisk), Ͻ.001 (dagger), and .004 (double dagger) (unpaired t test). In addition, the activity of 5␣-R was significantly greater than both the reductive and oxidative activity of 17␤-HSD in sebaceous glands from both men and women. 
TISSUE ENZYME ACTIVITIES IN MEN COMPARED WITH WOMEN
The activity of 5␣-R was significantly greater in SGs from men compared with glands from women. In addition, the oxidative activity of 17␤-HSD was 2-to 3-fold higher in SGs from men compared with women. As a reversible enzyme, 17␤-HSD can either produce the potent androgen testosterone (via reduction) or, in effect, "inactivate" it by converting it back to androstenedione (via oxidation). The type 2 isozyme of 17␤-HSD is active in human SGs. This isozyme prefers to oxidize testosterone to its less active precursor. In this regard, it has been suggested that the oxidative activity of the type 2 isozyme may protect target tissues (such as the SG) from the effects of potent androgens. 24 In this study, there was not much difference between the oxidative and reductive activities of 17␤-HSD. This is an artifact of the assay system, which uses homogenized glands that were provided with excess amounts of cofactors. In studies of intact SGs without added cofactors, the oxidative activity of 17␤-HSD predominates over its reductive activity by a much wider margin than in homogenized SGs.
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COMPARISON OF 5␣-R AND 17␤-HSD ACTIVITY IN SG
Few large studies have compared the activities of 17␤-HSD and 5␣-R in the same SG samples obtained from facial skin of both men and women. Our data demonstrate that 5␣-R is 2-to 4-fold more active than 17␤-HSD in sebaceous glands from both men and women. Both 5␣-R and the oxidative 17␤-HSD enzymes compete for testosterone as a substrate. With predominance of 5␣-R activity, the net effect within SGs is the conversion of testosterone to the more potent androgen DHT, which in turn is thought to mediate sebum production. Interestingly, the opposite is true in keratinocytes cultured from the infrainfundibulum of vellus follicles of forehead skin. 23 In these cells, the activity of 17␤-HSD is 2.5-to 8-fold greater than the activity of 5␣-R. Hence, vellus follicles from the face may be better protected from the effects of potent androgens than SGs because of predominance of 17␤-HSD oxidative activity over activity of 5␣-R.
THE ROLE OF SERUM ANDROGENS
Serum androgen levels were significantly higher in women with acne than in those without acne. Interestingly, these values were still within the normal range. No differences in serum androgen levels were noted in men on the basis of the presence of acne. Our data demonstrate that the highest specific activity of 17␤-HSD and 5␣-R was found in groups with the highest serum androgen levels. For example, enzyme activity was significantly greater in SGs from men than in those from women. Therefore, tissue enzyme activity may be proportional to serum androgen levels. Tissue enzyme activity correlated directly with serum androgen levels only in women without acne. Possible interpretations of these data include the following: (1) Serum levels of androgens may play a role in the development of acne in women by acting directly on SGs, by stimulating local tissue enzyme activity, or both. (2) Serum androgens are less important than nonhormonal factors in the pathogenesis of acne in men. (3) Tissue enzyme activity in men may be maximally stimulated by their serum levels of androgens.
The effects of androgens on acne are most evident in women. If serum androgens serve as substrates for sebaceous gland enzymes, women with acne may have greater tissue production of androgens than women without acne if the activity of 5␣-R is increased within their SGs. Alternatively, serum levels of androgens may be more important than locally produced androgens in modulating sebum production.
CONCLUSIONS
It is clear that acne is a multifactorial disease. Sebum is one part of the equation. Many men do not have acne despite their high levels of androgens compared with women. Furthermore, many individuals have high sebum production, yet they do not develop acne. Currently available hormonal therapies for acne act either to reduce the production of androgens by the adrenal gland or ovary or to inhibit the action of androgens at the target site (SG) by blocking the androgen receptor. This in turn leads to decreased sebum production. There are no hormonal therapies available that specifically block androgen-metabolizing enzymes within the SG. Such therapies may be beneficial in treating acne if sebum production is mediated by locally produced androgens. Whether sebum production is modulated by systemic androgens, locally produced androgens, or a combination of both still remains to be determined. This is one research question that will most likely be answered in the clinical setting as specific inhibitors of androgenmetabolizing enzymes become available.
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